A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-na ïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Condition:   Gastric Cancer Interventions:   Drug: ONO-4538;   Drug: Ipilimumab;   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: S-1 Sponsor:   Ono Pharmaceutical Co. Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials